{
  "id": 17808140,
  "title": "If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started",
  "url": "https://urgent.news/2026/11/02/if-modernas-ceo-is-right-the-stocks-rally-could-just-be-getting",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T14:19:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/02/if-moderna-s-ceo-is-right-the-stock-s-rally-could-just-be-getting-started/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Moderna, the hottest stock in the S&P 500 this year, has seen a remarkable 650% increase, with Sandisk coming in second at around 380%. The company's performance has been exceptional, despite recent struggles following a decline in demand for its COVID vaccine and pill. Now, there's significant excitement around Moderna due to a cancer vaccine it's developing in partnership with Merck. If the vaccine, intismeran, proves as effective as CEO Stéphane Bancel believes, the stock could potentially double. In a recent late-stage trial, intismeran reduced the risk of death or recurrence in melanoma patients when used with Merck's Keytruda by 42%. Bancel is optimistic that intismeran could work beyond melanoma, potentially unlocking massive growth for Moderna - Keytruda alone generated $32 billion in revenue for Merck last year. While Merck's market cap is around $370 billion, Moderna's valuation is less than $90 billion. Investors should tread carefully, as intismeran isn't approved yet, and while the results are encouraging, there's no guarantee of massive gains.",
  "summary": "Stéphane Bancel has high hopes for the company's cancer vaccine, beyond just treating melanoma.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}